Authors,Author(s) ID,Title,Year,Source tittle,Cited by,DOI,Country,Document Type,City,Access Type,aggregationType,EID
Lawrence M.,,Discovery and saturation analysis of cancer genes across 21 tumour types,2014,Nature,1596,10.1038/nature12912,United States,Article,Cambridge,0,Journal,2-s2.0-84892833777
Creighton C.J.,,Comprehensivemolecular characterization of clear cell renal cell carcinoma,2013,Nature,1633,10.1038/nature12222,United States,Article,Houston,1,Journal,2-s2.0-84879890360
Yoshino H.,,Aberrant expression of microRNAs in bladder cancer,2013,Nature Reviews Urology,152,10.1038/nrurol.2013.113,Japan,Review,Kagoshima,0,Journal,2-s2.0-84880253813
Wu Y.M.,,Identification of targetable FGFR gene fusions in diverse cancers,2013,Cancer Discovery,373,10.1158/2159-8290.CD-13-0050,United States;United States,Article,Ann Arbor;Ann Arbor,1,Journal,2-s2.0-84878781242
Lawrence M.S.,,Mutational heterogeneity in cancer and the search for new cancer-associated genes,2013,Nature,2675,10.1038/nature12213,United States,Article,Cambridge,0,Journal,2-s2.0-84880507665
Jaiswal B.,,Oncogenic ERBB3 Mutations in Human Cancers,2013,Cancer Cell,241,10.1016/j.ccr.2013.04.012,,Article,,1,Journal,2-s2.0-84877839648
Cibulskis K.,,Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples,2013,Nature Biotechnology,1959,10.1038/nbt.2514,United States,Article,Cambridge,1,Journal,2-s2.0-84874025843
Bose R.,,Activating HER2 mutations in HER2 gene amplification negative breast cancer,2013,Cancer Discovery,463,10.1158/2159-8290.CD-12-0349,United States;United States,Article,St. Louis;Detroit,1,Journal,2-s2.0-84873918443
Williams S.V.,,Oncogenic FGFR3 gene fusions in bladder cancer,2013,Human Molecular Genetics,235,10.1093/hmg/dds486,United Kingdom,Article,Leeds,1,Journal,2-s2.0-84873045850
Warfel N.,,P21WAF1 and tumourigenesis: 20 Years after,2013,Current Opinion in Oncology,193,10.1097/CCO.0b013e32835b639e,United States,Review,Hershey,0,Journal,2-s2.0-84871963013
Hurst C.D.,,Novel tumor subgroups of urothelial carcinoma of the bladder defined by integrated genomic analysis,2012,Clinical Cancer Research,62,10.1158/1078-0432.CCR-12-1807,United Kingdom,Article,Leeds,1,Journal,2-s2.0-84868537555
Iyer G.,,Genome sequencing identifies a basis for everolimus sensitivity,2012,Science,503,10.1126/science.1226344,,Short Survey,,0,Journal,2-s2.0-84867333656
Koboldt D.C.,,Comprehensive molecular portraits of human breast tumours,2012,Nature,6015,10.1038/nature11412,United States,Article,St. Louis,1,Journal,2-s2.0-84877028141
Ho P.,,Normal and neoplastic urothelial stem cells: Getting to the root of the problem,2012,Nature Reviews Urology,123,10.1038/nrurol.2012.142,United States,Review,Houston,0,Journal,2-s2.0-84867573207
Hammerman P.S.,,Comprehensive genomic characterization of squamous cell lung cancers,2012,Nature,2233,10.1038/nature11404,United States;United States,Article,Boston;Cambridge,1,Journal,2-s2.0-84866894408
Singh D.,,Transforming fusions of FGFR and TACC genes in human glioblastoma,2012,Science,425,10.1126/science.1220834,United States,Article,New York,0,Journal,2-s2.0-84865805666
Greulich H.,,Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2,2012,Proceedings of the National Academy of Sciences of the United States of America,170,10.1073/pnas.1203201109,United States;United States;United States;United States,Article,Boston;Boston;Boston;Cambridge,1,Journal,2-s2.0-84865994665
Ryan M.C.,,SpliceSeq: A resource for analysis and visualization of RNA-Seq data on alternative splicing and its functional impacts,2012,Bioinformatics,94,10.1093/bioinformatics/bts452,United States,Article,Fairfax,1,Journal,2-s2.0-84866464012
Sj√∂dahl G.,,A molecular taxonomy for urothelial carcinoma,2012,Clinical Cancer Research,374,10.1158/1078-0432.CCR-12-0077-T,Sweden,Article,Lund,1,Journal,2-s2.0-84862576866
Lindgren D.,,Integrated genomic and gene expression profiling identifies two major genomic circuits in urothelial carcinoma,2012,PLoS ONE,123,10.1371/journal.pone.0038863,Sweden,Article,Lund,1,Journal,2-s2.0-84862027456
Roberts S.A.,,Clustered Mutations in Yeast and in Human Cancers Can Arise from Damaged Long Single-Strand DNA Regions,2012,Molecular Cell,240,10.1016/j.molcel.2012.03.030,United States,Article,Research Triangle Park,1,Journal,2-s2.0-84861460657
Nik-Zainal S.,,Mutational processes molding the genomes of 21 breast cancers,2012,Cell,1010,10.1016/j.cell.2012.04.024,United Kingdom,Article,Hinxton,1,Journal,2-s2.0-84861541343
Gui Y.,,Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder,2011,Nature Genetics,491,10.1038/ng.907,China,Article,Shenzhen,0,Journal,2-s2.0-80052266351
Solomon D.,,Mutational inactivation of STAG2 causes aneuploidy in human cancer,2011,Science,280,10.1126/science.1203619,United States,Article,"Washington, D.C.",0,Journal,2-s2.0-80051874823
Oneyama C.,,MicroRNA-mediated downregulation of mTOR/FGFR3 controls tumor growth induced by Src-related oncogenic pathways,2011,Oncogene,77,10.1038/onc.2011.63,Japan,Article,Suita,1,Journal,2-s2.0-80051791926
Jemal A.,,Global cancer statistics,2011,CA Cancer Journal for Clinicians,27704,10.3322/caac.20107,United States,Article,Atlanta,1,Journal,2-s2.0-79952232216
Zhou J.,,"TXNIP (VDUP-1, TBP-2): A major redox regulator commonly suppressed in cancer by epigenetic mechanisms",2011,International Journal of Biochemistry and Cell Biology,65,10.1016/j.biocel.2011.09.005,Singapore,Short Survey,Singapore City,0,Journal,2-s2.0-80255134542
Forbes S.,,COSMIC: Mining complete cancer genomes in the catalogue of somatic mutations in cancer,2011,Nucleic Acids Research,1613,10.1093/nar/gkq929,United Kingdom,Article,Hinxton,1,Journal,2-s2.0-78651330430
Filippakopoulos P.,,Selective inhibition of BET bromodomains,2010,Nature,2150,10.1038/nature09504,United Kingdom,Article,Oxford,0,Journal,2-s2.0-78650847770
Vaske C.,,Inference of patient-specific pathway activities from multi-dimensional cancer genomics data using PARADIGM,2010,Bioinformatics,429,10.1093/bioinformatics/btq182,United States,Article,Santa Cruz,1,Journal,2-s2.0-77954195272
Goebell P.J.,,Bladder cancer or bladder cancers? Genetically distinct malignant conditions of the urothelium,2010,Urologic Oncology: Seminars and Original Investigations,143,10.1016/j.urolonc.2010.04.003,Germany,Review,Erlangen,0,Journal,2-s2.0-77953819013
Shibata T.,,Cancer related mutations in NRF2 impair its recognition by Keap1-Cul3 E3 ligase and promote malignancy,2008,Proceedings of the National Academy of Sciences of the United States of America,478,10.1073/pnas.0806268105,Japan,Article,Chuo-ku,1,Journal,2-s2.0-51649130168
Korpal M.,,The miR-200 family inhibits epithelial-mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2,2008,Journal of Biological Chemistry,1208,10.1074/jbc.C800074200,United States,Article,Princeton,1,Journal,2-s2.0-47249091921
Christofk H.,,The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth,2008,Nature,1778,10.1038/nature06734,United States,Article,Boston,0,Journal,2-s2.0-40749163248
Samowitz W.,,"Association of smoking, CpG island methylator phenotype, and V600E BRAF mutations in colon cancer",2006,Journal of the National Cancer Institute,222,10.1093/jnci/djj468,United States,Article,Salt Lake City,1,Journal,2-s2.0-33845672260
Von Der Maase H.,,"Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer",2005,Journal of Clinical Oncology,1089,10.1200/JCO.2005.07.757,Denmark,Article,Aarhus,0,Journal,2-s2.0-23044501890
Lehmann A.R.,,"The xeroderma pigmentosum group D (XPD) gene: One gene, two functions, three diseases",2001,Genes and Development,286,10.1101/gad.859501,United Kingdom,Review,Brighton,1,Journal,2-s2.0-0035176067
Tontonoz P.,,"Adipocyte-specific transcription factor ARF6 is a heterodimeric complex of two nuclear hormone receptors, PPAR7 and RXRa",1994,Nucleic Acids Research,306,10.1093/nar/22.25.5628,United States,Article,Boston,0,Journal,2-s2.0-0028593992
